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Executive Summary 
High-deductible health plans (HDHPs) are an important and growing part of the health 
insurance landscape. By some estimates, as many as 80 percent of large employers 
may offer an HDHP in 2014.i In 2013, more than 15 million Americans received health 
coverage through an HDHP, a more than a threefold increase since 2007.ii 
 
As outlined by the U.S. Treasury Department, individuals with an HSA-eligible HDHP are 
required to pay the full cost of most medications and services—in theory utilizing pre-
tax HSA funds—until deductibles are met.  However, the 2003 authorizing legislation 
and further guidance include a safe harbor allowing plans to cover primary preventive 
services, those typically deemed to prevent the onset of disease, before the 
deductible is satisfied.  
 
Services or benefits meant to treat “an existing illness, injury or condition,” are 
excluded from first-dollar coverage in HSA-eligible HDHPs, which encompasses most 
secondary preventive services.  For example, plans are prohibited from providing first 
dollar coverage of disease management services such as insulin, eye and foot exams, 
and glucose monitoring supplies for patients with diabetes.   
 
As chronic disease conditions currently make up 75 percent of total U.S. health 
spending,iii appropriate chronic disease management is an important tool to lower 
long-term health care costs.  As the market for HDHPs grow, it is important that they 
maintain the flexibility to allow for effective health management of all beneficiaries.  
This report addresses the strict definition of prevention that an HDHP must follow for it to 
include a pre-tax health savings account (HSA), and how this restriction limits the 
effectiveness of current plans.  A potential solution - allowing HSA-eligible HDHPs to 
provide first-dollar coverage for targeted, evidence-based, secondary preventive 
services that prevent chronic disease progression and related complications - can 
improve patient-centered outcomes, add efficiency to medical spending, and 
enhance HDHP attractiveness.  
 
A multi-disciplinary research team from the University of Michigan’s Center for Value-
Based Insurance Design, Harvard Medical School, and the University of Minnesota 
conducted a multi-part project to investigate the impact of updating  
the definition of prevention for HDHPs to include selected secondary preventive 
services that are frequently used as health plan quality metrics and included as 
elements of pay-for-performance programs.  Specifically, the project aimed to: 1) 
determine the premium effect, actuarial value, and estimated market uptake of the 
novel HDHP plan that covers these evidence-based services outside the deductible, 
and 2) explore through interviews whether insurance industry experts found coverage 
of secondary preventive services a worthwhile endeavor. 
  
i 
Quantitative analyses estimated that a novel, expanded HDHP plan would necessitate 
a 5-6% increase in premiums and would yield a slight increase in actuarial value.  
Simulation models revealed that the introduction of expanded HDHP would result in 
significant incremental HDHP adoption in commercial insurance markets.  
 
Qualitative interviews with an array of health insurance and employee benefit experts 
yielded diverse perspectives.  Many respondents indicated that expanding first-dollar 
coverage to secondary preventive services would be financially and ethically 
appropriate, while others felt that the existing HDHP structure was adequate. 
Respondents expressed openness to exploring ways to reduce the costs of their health 
care coverage and promote employee engagement, though many expressed 
ambiguity over whether HSA-eligible HDHPs are the right tool to address chronic 
disease care and management – even with the option to include certain secondary 
and tertiary services before the deductible.  
 
Utilizing the well-accepted and medically common definition of prevention that 
encompasses both primary and secondary preventive services could enhance HDHP 
attractiveness to potential purchasers and accelerate benefit design innovation. 
Expanding the definition of prevention to include evidence-based services that 
prevent chronic disease progression and related complications could enhance the 
ability of HDHPs to improve clinical outcomes while preserving the well-documented 
capacity to engage consumers and contain costs. 
  
ii 
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Background: Defining Prevention One Decade Ago 
As health care costs continue to consume an increasing percentage of the country’s 
employer and household budgets, high deductible health plans are a growing part of the 
health insurance landscape.  In 2013, nearly 60 percent of firms with more than 5,000 
workers offered an HDHP, either coupled with a health reimbursement arrangement (HRA) 
or health savings account (HSA). According to the 2013 annual health benefits survey by 
Towers Watson and the National Business Group on Health, 66 percent of companies with 
1,000 employees or more offered at least one such plan in 2013. This figure is expected to 
grow to nearly 80 percent in 2014, according to the survey.i Among nearly 15 percent of 
companies surveyed, a savings account-based plan was the only option available to 
employees—an increase from 7.6 percent in 2010.  Enrollment trends continue to rise with 
15.5 million Americans enrolled in HSA-eligible HDHPs in 2013, up from 6.1 million in 2008. 
Created by the Medicare Prescription Drug Improvement and Modernization Act of 2003, 
HSA-eligible HDHPs have defined minimum deductibles and maximum out of pocket limits.  
For 2014, the minimum deductible is $1,250 for an individual and $2,500 for a family; 
maximum out-of-pocket limits are $6,350 for an individual and $12,700 for a family.iv  HSAs 
allow beneficiaries to put a set amount of money in a tax-advantaged account to be 
used for medical expenses.  The Internal Revenue Service (IRS) regulated savings accounts 
do not expire, are portable (not attached to employment, solely to the account holder) 
and can accept contributions from both account holders and employers. 
In general, to qualify as an HDHP, a plan may not cover medical services or products until 
the deductible is satisfied; the idea is that the beneficiary will pay out of pocket utilizing 
pre-tax HSA dollars. However, the statute includes a preventive care safe harbor via 
Section 223 of the Internal Revenue Code.  Section 223(c)(2)(C) states  “[a] plan shall not 
fail to be treated as a high deductible health plan by reason of failing to have a 
deductible for preventive care (within the meaning of section 1871 of the Social Security 
Act, except as otherwise provided by the Secretary).”v  Per IRS notice 2004-23 (2004-15 
I.R.B. 725), “a HDHP may therefore provide preventive care benefits without a deductible 
or with a deductible below the minimum annual deductible.”vi  
However, preventive care is not clearly defined by the law and part of the confusion may 
stem from the reference to Section 1871 of the Social Security Act (SSA), which appears to 
be a typographical error.vii Section 1861 of the SSA, likely the intended reference, defines 
preventive services as they pertain to an initial preventive physical examination for 
Medicare, a one-time service offered to newly enrolled Medicare beneficiaries.viii  In this 
definition of prevention, section 1861 includes certain vaccinations, screenings for a 
number of conditions including common cancers, cardiovascular problems and diabetes, 
services with a grade A or B recommendation from the U.S. Preventive Services Task Force 
and other services “reasonable and necessary for the prevention or early detection of an 
illness or disability.” There is no explicit definition of prevention for non-Medicare 
populations in the MMA legislation. 
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IRS notice 2004-23 provides guidance on preventive care benefits allowed to be provided 
by an HSA-qualified HDHP without satisfying the minimum deductible requirement. 7 These 
benefits include, but are not limited to, periodic health evaluations, routine prenatal and 
well-child care, child and adult immunizations, tobacco cessation programs, obesity 
weight-loss programs, and a number of screening services.  Typically, these services are 
deemed primary preventive services.  
IRS notice 2004-23 also states “preventive care does not generally include any service or 
benefit intended to treat an existing illness, injury, or condition” [emphasis added]. 7  In the 
notice, the IRS requests comments on the “extent to which drug treatments, either solely 
by prescription or as part of an overall treatment regimen should be treated as preventive 
care and the appropriate standards for differentiating between drug treatments that 
would be considered preventive care and those that would not be considered preventive 
care”.   
Question and answers 26 and 27 of Notice 2004-50 (2005-33 I.R.B. 196), presumably written 
in response to the comments received, refer to prevention as a continuous activity that in 
certain clinical circumstances can include services used by a person who has been 
diagnosed with manifestations of disease, such as heart attack or stroke.ix Heart attack 
and stroke are deemed markers of chronic disease, either coronary artery disease or 
cerebrovascular disease, with the goal of preventing progression or complications.  
Specifically, IRS notice 2004-50 states: 
Solely for this purpose, drugs or medications are preventive care when taken 
by a person who has developed risk factors for a disease that has not yet 
manifested itself or not yet become clinically apparent (i.e., asymptomatic), 
or to prevent the reoccurrence of a disease from which a person has 
recovered. For example, the treatment of high cholesterol with cholesterol-
lowering medications (e.g., statins) to prevent heart disease or the treatment 
of recovered heart attack or stroke victims with Angiotensin-converting 
Enzyme (ACE) inhibitors to prevent a reoccurrence, constitute preventive 
care. In addition, drugs or medications used as part of procedures providing 
preventive care services specified in Notice 2004-23, including obesity 
weight-loss and tobacco cessation programs, are also preventive care. 
However, the preventive care safe harbor under section 223(c)(2)(C) does 
not include any service or benefit intended to treat an existing illness, injury, 
or condition, including drugs or medications used to treat an existing illness, 
injury or condition. 
The exclusion spelled out in the last sentence above encompasses the bulk of secondary 
preventive services and prohibits health plans from offering these benefits before enrollees 
meet their deductibles. This exclusion also precludes purchasers from pursuing many 
proven disease management strategies.  For example, HSA-eligible HDHPs are prohibited 
from providing first dollar coverage of disease management services including insulin, eye 
and foot exams, and glucose monitoring supplies for patients with diabetes until after the 
deductible is reached.  
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Updating the Definition of Prevention 
Legislative efforts have recognized the desirability of promoting primary preventive 
services as a way to encourage both sound fiscal and health policy. Notably, section 2713 
of the Public Health Service Act (which was created in the Patient Protection and 
Affordable Care Act) requires that new health plans, including HDHPs, include first-dollar 
coverage of selected, evidence-based primary preventive services.x,xi 
Primary prevention, while important, is a small component of overall health spending. By 
contrast, spending on chronic disease encompasses more than 75 percent of total U.S. 
health expenditures.xii  Published literature supports that when individuals with chronic 
disease forego recommended services, it not only impacts their health, but also can result 
in higher aggregate costs.xiii,xiv  Reducing financial barriers to evidence-based care for 
chronic conditions offers an opportunity to substantially enhance clinical outcomes and 
reduce the long- term rate of healthcare spending growth.xv 
Within HDHPs specifically, there is evidence that a focus on secondary prevention could 
be beneficial. One study found that patients who have HDHPs and chronic disease are 
more likely to go without care due to cost than those with chronic disease who have 
traditional plans. xvi   Another study found that among families in which at least one 
member had a chronic condition, 48 percent covered by an HDHP faced substantial 
financial burdens such as trouble paying bills, compared with 21 percent in traditional 
plans. xvii  As HDHPs continue to grow and encompass a larger percentage of the 
population, these patterns could impact overall health care costs and health quality.  
Though there are a number of definitions of secondary prevention, the Center for Value-
Based Insurance Design recommends it be defined as the prevention of complications 
from, or progression of, chronic disease.  Chronic disease is defined by the Centers for 
Disease Control and Prevention as non-communicable illnesses that are “prolonged in 
duration, do not resolve spontaneously and are rarely cured completely,” including heart 
disease, cancer, diabetes and obesity.xviii Notably, these types of secondary preventive 
services are frequently used as quality metrics by health plans and used as element of 
pay-for-performance initiatives for providers.  
The V-BID Center also suggests utilizing recommendations from medical societies 
pertaining to chronic disease management to inform the definition of secondary 
prevention. For example: 
 The American Diabetes Association recommends patients with type II 
diabetes mellitus receive the following: annual eye exams, annual 
comprehensive foot exams, annual screening for kidney disease, diabetes 
self-management education at the time of diagnosis, metformin as the 
preferred initial agent for glycemic control, ACE inhibitors in patients with 
diabetes who have high blood pressure or increased urinary protein 
excretion, statins in patients with diabetes over age 40 with risk factors for 
cardiovascular disease, and other secondary preventive services.xix 
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 The American Heart Association (AHA) and American College of 
Cardiology Foundation (ACCF) joint guideline on secondary prevention for 
patients with coronary and other atherosclerotic vascular disease finds 
evidence to support therapy with statins for lipid control, beta-blockers or 
ACE inhibitors for blood pressure control, aspirin, ACE inhibitors for patients 
with ejection fractions less than 40%, and several other pharmacologic 
agents in selected patients to prevent exacerbations and complications.  
AHA and ACCF also urge comprehensive cardiac rehabilitation following 
coronary artery bypass surgery or percutaneous coronary intervention.xx 
 
 The United States Multi-Society Task Force on Colorectal Cancer guideline 
on colonoscopy surveillance after polyp removal finds evidence to support 
secondary follow-up colonoscopies at intervals less than the ten years used 
for primary prevention.xxi 
 
 The American Association for the Study of Liver Disease and American 
College of Gastroenterology find strong evidence to support nonselective 
beta-blocker therapy for prevention of variceal hemorrhage in patients 
with cirrhosis who have medium to large varices that have not bled.xxii 
Additionally, the multiple chronic conditions working group within the HHS Office of the 
Assistant Secretary of Health selected 20 chronic conditions for a standard classification 
scheme and the IRS could link to this list in defining chronic disease.  The list of 20 includes: 
hypertension, congestive heart failure, coronary artery disease, cardiac arrhythmias, 
hyperlipidemia, stroke, arthritis, asthma, autism spectrum disorder, cancer, chronic kidney 
disease, chronic obstructive pulmonary disease, dementia, depression, diabetes, hepatitis, 
human immunodeficiency virus, osteoporosis, schizophrenia, and substance abuse 
disorders.xxiii  This list could further inform the definition of secondary prevention.     
As regulators consider the pros and cons of updating the definition of prevention, they will 
likely struggle with determining how to strike the right balance between ensuring entities 
have flexibility to design plans aimed at preventing progression and complications 
associated with chronic conditions and also ensuring the definition appropriately limits 
what services may be offered before the deductible is met.   
To better understand the likely impact of an updated definition of prevention on HDHP 
design, price and uptake, a multi-disciplinary of researchers from the University of 
Michigan, Harvard Medical School and the University of Minnesota undertook a multi-part 
quantitative and qualitative analysis of the issue.  Specifically, the research projects aimed 
to 1) determine the premium effect, actuarial value, and estimated market uptake of a 
novel expanded HDHP plan, and 2) explore through interviews whether health care 
experts found coverage of secondary preventive services a worthwhile endeavor and 
whether they felt these products would be attractive to employers and employees.   
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Project Overviews 
Quantitative Assessment 
RESEARCH AIMS:  
The aims of the quantitative research were to estimate three specific outputs related to 
the potential coverage of targeted, evidence based secondary preventive services under 
the deductible in a HSA-qualified high-deductible health plan.  
1) Determine changes in utilization of, and spending on, targeted secondary 
prevention services that result from a reduction in consumer out-of-pocket 
spending for these services; 
 
2) Estimate the impact of increased utilization of the targeted services on 
aggregate spending and HSA-HDHP premiums;  
 
3) Approximate the uptake of the expanded HSA-HDHP plan in commercial 
markets.  
METHODS: 
Selection of Secondary Preventive Services:  Commonly used, secondary prevention 
services that are frequently used in health plan quality metrics and elements of clinician 
pay-for-performance programs were selected.  These services have been previously 
identified in the published literature.xxiv  
Data Source:  Truven MarketScan Commercial Claims and Encounters (MarketScan) data 
from 2011 were utilized. The data are comprised of commercial hospital, physician, and 
drug claims with their associated spending amounts, as well as procedure and diagnosis 
codes.  These data encompass 52 million enrollees per year in over 150 large private 
employers and health plans, and include a range of demographic and enrollment 
information.  Enrollees include employees, spouses, and dependents, all of which are 
covered in commercial plans.  Pharmaceutical claims are available for approximately 
80% of enrollees.  
MarketScan data include out-of-pocket components of spending (copayment, 
coinsurance, and deductible) as well as the payer contribution and any coordination of 
benefits or discounts. As displayed in Table 1, Selected secondary prevention services in 
were identified in the MarketScan data based on Current Procedural Terminology (CPT) 
codes for medical services, labs, and screening and National Drug Codes (NDCs) for 
prescription drugs. 
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Table 1. Secondary Preventive Services Evaluated 
ACE Inhibitors Medications that control blood pressure for 
patients with: congestive heart failure, coronary 
artery disease (after myocardial infarction), and 
diabetes 
Anti-resorptive Therapy Medications for patients with osteoporosis and 
osteopenia 
Beta-Blockers Medications for patients with: congestive heart 
failure and coronary artery disease (after 
myocardial infarction) 
Blood Pressure Monitor Equipment for patients with hypertension to 
monitor blood pressure 
Inhaled Corticosteroids Medications for patients with asthma 
Glucose Lowering Agents Medications for patients with diabetes 
Retinopathy Screening  For patients with diabetes 
Peak Flow Meter Equipment for patients with asthma 
Glucometer Equipment that monitors blood sugar levels for 
patients with diabetes 
Hemoglobin A1c testing Monitors blood sugar for patients with diabetes 
INR testing Measure blood coagulation for patients on 
certain drugs that thin blood 
LDL testing Measures blood cholesterol level for patients at 
risk for, or diagnosed with heart disease 
SSRIs Antidepressant medications for patients with 
Major Depression 
Statins Cholesterol-lowering medications for patients at 
risk for, or diagnosed with heart disease 
and patients with diabetes 
 
Analytical Approach:  A two-stage approach was used to estimate the impact of the 
change in coverage of secondary preventive services in a novel, expanded HDHP.  The 
first stage evaluated the resultant effect the change in plan design on utilization and 
premiums; the second estimated the potential uptake of the expanded HDHP in 
commercial markets.  
I. IMPACT OF DEDUCTIBLE CHANGES ON UTILIZATION AND PREMIUMS: 
 
a) Baseline utilization and spending patterns for patients in HDHP plans were determined 
based on in-network deductible spending for enrollees who had total medical 
expenditures exceeding a certain threshold ($2,500) in a given calendar year.  The 
distribution of deductible spending was then matched to the yearly IRS definition of a 
qualified health plan that sets the minimum individual and family deductible needed for a 
plan to qualify as a HDHP.  
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b) Estimating utilization and spending in HSA-HDHP that includes secondary prevention 
assumed that the expanded plan’s covered benefits remain the same except for the 
specified high-value preventive services that are now covered before the deductible.  
Reducing the amount a consumer spends out-of-pocket impacts aggregate spending 
(and thus premiums) in several ways:  
1. Shift Effect: The insurer incurs any cost that the consumer no longer pays since 
the overall price of the service is unchanged. This is a shift in cost from the 
patient to the insurer. We calculate this shift in the first stage of the analysis by 
shifting all out-of-pocket expenditure on the selected services to the plan, 
holding utilization and total expenditure the same.  
 
2. Utilization Effect: A change in spending occurs because a decrease in out-of-
pocket spending increases the utilization of the drug or service. The amount 
of this change in consumption is relative to the price-elasticity of demand 
(percent change in utilization / percent change in price) of a given service. 
Elasticity estimates from the seminal RAND Health Insurance Experiment - the 
only randomized trial to measure the impact of out-of-pocket costs on the 
use of medical care – was used.xxv  
 
3. Offset Effect: There is now relevantly robust evidence that increased 
consumption of medications and high-value secondary preventive services 
will result in some reduction in other medical expenditures such as 
hospitalizations. In 2012 the Congressional Budget Office (CBO) started 
allowing an increase in prescription drug use to be somewhat offset by a 
decrease in medical expenditure when scoring legislation.xxvi  Calculating the 
precise offset for each of the selected drugs and services was out of the 
scope of this work. Our base case estimates on spending assume no offset.  A 
sensitivity analysis assumed offsets similar to what the CBO allows (assuming a 
1/5th of 1 percent decrease in medical spending for every 1 percent increase 
in prescriptions filled); a similar magnitude of offset was also assumed for non-
drug services. It is worth noting that the conservative CBO methodology may 
significantly underestimate the offset from these secondary preventive 
services that were selected because of their value. 
 
4. Selection Effect: Increasing the benefit generosity of a plan can also change 
expenditure and premiums because more generous plans will attract 
patients who are more likely to incur higher costs than those covered in a 
less-generous plan. This “selection” impact is incorporated in the modeling 
section of the analysis. 
 
c)  The change in premium was calculated assuming that the population enrolled in the 
specific HDHP remains constant.  This is equivalent to assuming a captive population 
similar to an employer fully replacing their current HDHP with this novel product.  Generally, 
an insurance premium is a function of total medical and drug expenditure paid by the 
health plan and a loading factor that includes administration, marketing, and other non-
care related expenditure. Since MarketScan does not contain information about a plan-
loading factor, it was assumed to remain proportional to the overall premium. Actuarial 
value was estimated as the percent of medical and drug spending paid by the health 
plan. 
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II. POTENTIAL UPTAKE OF THE EXPANDED HDHP IN COMMERCIAL MARKETS 
The ARCOLA micro-simulation model was used to forecast the movement of individuals 
across different types of health plans (e.g. PPO, HDHP, uninsured) as the premiums and 
generosity of plans change.  Holding a plan’s generosity constant, an increase in premium 
would decrease the demand for a certain type of plan.  Correspondingly, an increase in 
the generosity of a plan (i.e. the actuarial value) will increase demand.  
ARCOLA was developed originally under contract from Department of Health and Human 
Services and designed specifically to gauge the effect of CDHP demand in different 
health reform scenarios.  The methods and results of the model have been published in 
the peer-reviewed literature for nearly a decade.xxvii,xxviii 
The ARCOLA micro-simulation contains an array of health plans commonly available 
including HMOs and four Preferred Provider Organizations (PPOs) that correspond to the 
ACA metallic categories (i.e., platinum, gold, silver, bronze). In the bronze categories, a 
narrow network PPO and a HDHP are included.  All of these choices are available in the 
individual as well as the employer-sponsored health insurance market with the addition of 
a HRA design.  
To create the expanded HDHP in the simulation model, the incremental generosity of the 
novel plan needed to be accounted for.  Previously published studies that examined 
factors leading to plan choice (e.g., PPOs and HDHP) selected by chronically ill individuals 
were used to estimate the incremental generosity of the expanded HDHP used in the 
micro-simulation. xxix 
Once premium and plan generosity effects of expanded coverage of selected 
secondary preventive services were quantified, a novel HDHP plan was added to the plan 
choice mix in both the individual and the employer market.  The simulation was able to 
identify the demand for the new expanded HDHP product as well as overall impact of the 
uninsured.  For the micro-simulations, populations with statistic weights for individuals to 
generalize to the United States are deployed including state-specific differences in 
Affordable Care Act (ACA) adoption due to Medicaid expansion becoming a state 
decision following the 2012 Supreme Court case regarding the ACA.xxx 
RESULTS:  
I. IMPACT OF DEDUCTIBLE CHANGES ON UTILIZATION AND PREMIUMS: 
1.05 million eligible enrollees were identified in MarketScan (i.e. data for a full year) and 
enrolled in HDHPs in 2011. The actuarial value of baseline HDHP plans was 71.7%.  The 
selected secondary preventive services accounted for 6.1% of spending in currently 
available HDHPs, which constituted a $321 per member per month (PMPM) expenditure.  
The total and out-of-pocket spending for each of the targeted services is presented in 
Table 2.   
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Table 2. Spending on Targeted Preventive Services  
Service Spending 
($ Thousands) 
Copay 
($ Thousands) 
Percent OOP 
ACE Inhibitors $589,769 $214,621 36% 
Anti-resorptive Therapy $230,400 $90,537 39% 
Beta Blockers $171,807 $62,247 36% 
Blood Pressure Monitor $369 $89 24% 
Inhaled Corticosteroids $17,432 $8,593 49% 
Glucose Lowering Agents $944,697 $199,599 21% 
Retinopathy Screening  $207,430 $88,566 43% 
Peak Flow Meter $169 $54 32% 
Glucometer $19,330 $4,882 25% 
Hemoglobin A1c Lab $369,662 $99,682 27% 
INR Lab $5,129 $943 18% 
LDL Lab $6,452 $2,635 41% 
SSRIs $18,812 $9,604 51% 
Statins $878,337 $297,595 34% 
 
Expanding coverage for the targeted services led to a 5.63% increase in premium 
(assuming no offset).  2.66% of the premium increase was due to the shift of payments 
from patients to the health plan, and 2.97% of the increase in premium was due to the 
increased utilization of services.  An analysis using the CBO offset estimate resulted in a 
slightly lower premium increase of 5.08%.  
Table 3. Change in PMPM Premiums from Baseline HDHP 
 Assuming No Offset Assuming Offset 
PMPM Premium, Baseline HDHP $320.72 $320.72 
Percent Change Due to Shift  2.66% 2.66% 
Percent Change Due to Elasticity 2.97% 2.97% 
Percent Change Due to Offset 0% -0.56% 
Total Percent Change 5.63% 5.08% 
PMPM Premium, Novel HDHP $338.78 $337.00 
 
The actuarial value of the novel HDHP rose to 74.18% when assuming no offset and to 
74.20% when the offset was included (Table 4). 
Table 4. Impact of Coverage on Actuarial Value 
 Baseline 
HDHP 
Novel HDHP, 
No Offset 
Novel HDHP 
Offset 
Plan Spending PMPM $320.72 $338.78 $337.00 
Out-of-Pocket PMPM $126.42 $117.89 $117.19 
Actuarial Value (%) 71.72% 74.18% 74.20% 
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II. POTENTIAL UPTAKE OF THE EXPANDED HDHP IN COMMERCIAL MARKETS 
Individual Market 
The ARCOLA simulation estimated that the introduction of the novel HDHP plan will lead to 
overall increase in insurance coverage in the individual insurance market (Figure 1).  If the 
expanded HDHP plan was introduced in 2014 among all the other competing plan 
choices, it would be in high demand for over 5.5 million individuals.  When examined over 
time, the new HDHP remains the fastest growing plan design until 2018 at which point, 
premium price for the current HDHP is sufficiently less expensive than the expanded HDHP.  
The simulation estimates that both HDHP and expanded HDHP enjoy considerable growth 
over the 2014 to 2023 period compared to PPO in the individual insurance market.  Several 
sensitivity analyses revealed the both the chronically ill and less so those without chronic 
illness responded positively to the new HDHP choice.   
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Figure 1. Forecast of  Insurance Uptake Change  
by Plan Type (millions) in the Individual Insurance Market 
HDHP HDHP+ PPO
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Employer-sponsored Market 
Figure 2 demonstrates the substantial potential impact of introducing the expanded HDHP 
into the employer-sponsored health insurance market.  The ARCOLA model projects, that 
if the novel plan was introduced in 2014, the expanded HDHP would be very popular in 
this market.  However, it would be a significant substitute for existing HRA plans.  This trend 
persists until 2023.  The only significant change is that the expanded HDHP becomes more 
popular than the current HDHP over time.  
 
 
 
When the ARCOLA model allowed employees to buy the expanded HDHP in exchanges, 
there is the potential for high demand, mostly from the existing employer sponsored PPO 
market.  Of a roughly 160 million covered life employer market, approximately 40 million at 
the maximum may find the novel HDHP attractive, particularly if income-based cost-
sharing reductions and premium credits are combined with the lower price point of 
expanded HDHP which has more generous benefits. 
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LIMITATIONS: 
This research faces several important limitations.  These analyses do not directly account 
for the impact of a health savings account (HSA) on the use of services either in the 
baseline or in the hypothetical new plan offering.  The influence of a HSA, especially one 
seeded by an employer, was beyond the scope of this work.  This might have the effect of 
reducing the utilization effect and therefore reducing the premium increase, but also 
reducing the increase in actuarial value of the novel plan. 
Importantly, the estimates presented are based only on the impact of enhanced 
coverage of selected high value secondary preventive services.  The analysis did not 
examine benefit design or care-coordination mechanisms such as implementing disease 
management programs.   
SUMMARY OF QUANTITATIVE RESULTS: 
 Targeted secondary prevention services represent ~6% of total spending 
in existing HDHPs; 
 
 The novel expanded HDHP plan would necessitate an estimated 5-6% 
increase in premiums. Approximately half of the added spending resulted 
from increases in plan costs shifted from existing users of targeted services, 
and half resulted from increased utilization by new users; 
 
 Expanded HDHP results in a slight increase in actuarial value 
 
 Introduction of expanded HDHP leads to significant HDHP growth in 
commercial markets  
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Qualitative Interviews 
STAKEHOLDER CONVERSATIONS ABOUT HEALTH SAVINGS ACCOUNT-ELIGIBLE  
HIGH DEDUCTIBLE HEALTH PLANS 
To expand the health care research lexicon on HDHPs, the University of Michigan Center 
for Value-Based Insurance Design completed a series of qualitative interviews with an 
array of health care stakeholders in the employer and insurance market to discuss the 
benefits and deficits of existing HSA-eligible HDHPs as well as how the creation of a value-
based HDHP plan that included first-dollar coverage of chronic disease services might 
impact premiums, chronic disease management and plan uptake.  The Center sought the 
perspective of insurance plan designers, employers who offer HSA-eligible HDHPs as “full 
replacement plans,” employers who offer the HSA-eligible HDHPs alongside more 
traditional plans, and employers who did not offer an HSA-eligible HDHPs and did not 
intend to in the immediate future.  The interviews focused on implementation successes 
and challenges that HSA-eligible HDHPs might pose to employers and consumers, as well 
as which categories of preventive services were currently covered prior to satisfaction of 
the deductible.  Respondents were also asked to identify what specific medical goods 
and services might be covered in a hypothetical new plan that offered secondary and 
tertiary preventive services for chronic disease management prior to satisfaction of the 
deductible.     
The breakout of respondents included: 
 Three representatives from managed health care organizations that offer 
HSA- and HRA-eligible HDHPs in addition to other forms of coverage for 
over 37.6 million lives on the individual, small and large group market; 
 
 Three large, for-profit organizations with over 100,000 domestic and 
international employees and retirees who currently do not offer an HDHP; 
 
 One for-profit employer organization that offered full replacement HSA-
eligible HDHP to all salaried employees totaling approximately 17,000 
employees; 
 
 One health system employer with over 20,000 employees that recently 
began offering an HSA-eligible HDHP; 
 
 One medical provider corporate consultant; 
 
 One labor-based employer offering full replacement HSA-eligible HDHP to 
non-negotiated non-unionized management of approximately 1500 
employees; 
 
 Three large employers totaling over 200,000 employees who offer HSA-
eligible HDHPs alongside other plans. 
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KEY TAKEAWAYS 
 
The combination of the rapidly increasing uptake of HDHPs and the growing prevalence 
of chronic disease in the U.S. suggest that rendering these plans more effective tools for 
disease management is a worthwhile endeavor. Participants in the interviews confirmed 
that HDHPs in their current form are not ideal products for those with chronic illnesses and 
offered worthwhile suggestions on how that might be changed. 
 
 There is a need to evaluate the effect these plans have on users’ health 
behavior and overall health care costs as there is some evidence that 
higher consumer cost sharing before the deductible may lead some to 
avoid obtaining both necessary and unnecessary care. 
 Avoidance of routine and preventive health care, particularly pertaining 
to chronic disease management, results in more costly complications and 
poor health outcomes. 
 
Participants offered diverse perspectives in their discussion of HSA-eligible HDHPs, 
producing a series of supplemental considerations regarding plan benefits, insufficiencies 
and possible improvements.  
 
 Respondents noted that HDHPs have the potential to raise consumer 
responsibility and participation in their health care utilization; however, they 
also noted that without proper education and communication measures 
prior to implementation, these plans may result in decreased utilization of 
necessary treatment, including chronic disease services, as a measure to 
avoid out-of-pocket costs. 
 Participants also recognized that the plans in their current form may not meet 
the needs of select populations including those living with multiple conditions, 
older populations, those who must manage non-generic prescription drug 
costs and those of lower socio-economic status. 
 Respondents indicated that some of these concerns can be overcome 
through the utilization of a variety of consumer education and 
communication tools, combined with seed money to offset the deductible 
and greater employer engagement. 
Participants offered measured insights regarding federal regulations that currently define 
primary preventive services and therefore structure first-dollar coverage requirements prior 
to satisfaction of the deductible. 
 
 Some respondents felt that primary preventive services—services classified as 
“A” or “B” grade services by the United States Preventive Services Task 
Force—were adequate to cover at no-cost prior to satisfaction of the 
deductible, stating that the intent of offering an HDHP was to provide 
essential service coverage while encouraging consumers to participate in 
their own care to meet the deductible.  
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 Others felt that expanding primary prevention first-dollar coverage to include 
low-cost disease management strategies (so-called “secondary preventive 
benefits”) would be financially and ethically appropriate to encourage those 
living with chronic disease to seek and access care. However, current federal 
regulations and a lack of recommendations similar to primary prevention 
guidelines made the process difficult.  
 Additional respondents voiced that increasing access to disease 
management strategies prior to the deductible might be responsible health 
stewardship, however, these coverage decisions must be evidence-based, 
consistently coded by providers, better aligned with current reform efforts 
including wellness initiatives, and offered by high-performing providers and 
facilities.  
While respondents were interested in exploring ways to reduce the costs of their health 
care coverage and promote employee engagement, they expressed ambiguity as to 
whether HSA-eligible HDHPs are the right tool to address chronic disease care and 
management, even with the option to include secondary and tertiary services as first-
dollar covered services. 
 
Additional examination is necessary to explore how these plan designs and saving options 
impact how employers and consumers—particularly consumers living with or diagnosed 
with a chronic condition—comprehend, utilize, and pay for care. 
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Possible Solutions 
 
Using the current, narrow definition of prevention in the IRS guidance, HDHPs are limited in 
their ability to effectively manage chronic conditions.  A possible solution is to update the 
definition of prevention under the guidance to reflect the clinical notion that prevention 
includes not just primary prevention, but also secondary prevention of chronic disease.  
Updating the guidance to allow coverage of secondary preventive services would 
encourage better health and more efficient healthcare spending.  Broadening the 
existing safe harbor would allow HDHPs to provide coverage for selected evidence-based 
clinical services that prevent the progression of, or complications from, chronic disease 
without a deductible or with a deductible below the annual minimum. 
One suggestion is to amend IRS guidance to include this sentence:  
The preventive care safe harbor under section 223(c) (2) (C) may include any service or 
benefit, including drugs and medications, intended to prevent chronic disease progression 
or complications. 
An important distinction is that this recommendation would allow but not mandate that 
HDHPs cover, wholly or in part, secondary preventive services before the deductible, 
giving plans the flexibility to cover or not cover secondary preventive services and 
products.  
It is important to recognize the difference between this potential update and previous 
efforts to extend coverage to certain types of preventive services. Within the Patient 
Protection and Affordable Care Act, for example, coverage of certain primary preventive 
services is mandated for all new plans without patient cost sharing.  
In contrast, the suggestion to update the definition of prevention would encourage 
purchasers to alter their plans as much or as little as they see fit within existing laws. The 
update would offer plans the flexibility to change, but not the requirement that they do so. 
The implementation of this update could vary widely depending on the preferences of the 
individual purchaser.   
The proposed, updated definition permits HDHPs to better serve beneficiaries, particularly 
Americans diagnosed with chronic disease. Expanding the definition of prevention to 
include services that prevent chronic disease progression and related complications 
would enhance the ability of HDHPs to improve clinical outcomes while preserving the 
well-documented capacity to engage consumers and contain costs. 
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Conclusion 
Updating the existing definition of prevention to include services used in the management 
of chronic disease allows for better health outcomes and more efficient spending of 
health care dollars.  Utilizing the well-accepted and medically common definition of 
prevention that encompasses both primary and secondary preventive services would 
enhance HDHP attractiveness to potential purchasers and accelerate benefit design 
innovation.  Amending the definition would ultimately allow health insurers to create 
products that better address the important goals of quality improvement and cost 
containment.  
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